Study to measure the effectiveness of the Budesonide/formoterol electronic multidose dry powder inhaler (BF Digihaler) Digital System (DS)

Study Title
CONNected Electronic Inhalers Asthma Control Trial 3 ("CONNECT 3"), a 24-Week Treatment, Multicenter, Open Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus the Budesonide/Formoterol Digihaler Digital System, to Optimize Outcomes in Adult Patients with Asthma
Teva Identifier
BFS-AS-40184
ClinicalTrials.gov Identifier
N/A
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: Budesonide/Formoterol Digihaler Digital System
EudraCT Number
2021-003951-41
Study Description
The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care group
Print

EudraCT
respiratory-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and older
Trial Duration
January 23, 2023 - June 29, 2023
Phase
Phase 4

Study Type

Interventional